Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. has achieved a significant milestone by successfully producing 5,000 doses of its synthetic anti-infective RECCE® 327 per week under stringent Good Manufacturing Practice (GMP) conditions, in readiness for current and future clinical trials. This accomplishment showcases the company’s scalable manufacturing prowess and adherence to regulatory standards, essential for its Investigational New Drug (IND) submission. The advancement is a critical step in combating antimicrobial resistance and progressing towards new treatments for infections such as Diabetic Foot Ulcer.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
